Parnassus Investments LLC Acquires 9,474 Shares of Thermo Fisher Scientific Inc. $TMO

Key Points

• Parnassus Investments LLC increased its stake in Thermo Fisher Scientific by 0.7%, acquiring an additional 9,474 shares, bringing its total to 1,420,431 shares, which represent approximately 1.7% of its investment portfolio.
• Thermo Fisher reported a quarterly earnings per share (EPS) of $5.36, surpassing analysts' expectations of $5.22, with a revenue of $10.86 billion for the quarter, showing a year-over-year increase of 2.9%.
• The company declared a quarterly dividend of $0.43, set to be paid on October 15, with an annualized dividend yield of 0.4% and a payout ratio of 9.95%.

Parnassus Investments LLC lifted its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 0.7% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,420,431 shares of the medical research company's stock after purchasing an additional 9,474 shares during the period. Thermo Fisher Scientific comprises approximately 1.7% of Parnassus Investments LLC's investment portfolio, making the stock its 24th largest holding. Parnassus Investments LLC owned 0.38% of Thermo Fisher Scientific worth $706,806,000 as of its most recent SEC filing.

Other hedge funds also recently made changes to their positions in the company. Cypress Advisory Group LLC bought a new stake in shares of Thermo Fisher Scientific during the 4th quarter worth $253,000. Mondrian Investment Partners LTD increased its holdings in Thermo Fisher Scientific by 146.1% in the 1st quarter. Mondrian Investment Partners LTD now owns 214,506 shares of the medical research company's stock worth $106,738,000 after acquiring an additional 127,357 shares during the last quarter. GAMMA Investing LLC increased its holdings in Thermo Fisher Scientific by 22.0% in the 1st quarter. GAMMA Investing LLC now owns 4,862 shares of the medical research company's stock worth $2,419,000 after acquiring an additional 877 shares during the last quarter. Deutsche Bank AG increased its holdings in Thermo Fisher Scientific by 9.5% in the 4th quarter. Deutsche Bank AG now owns 1,321,633 shares of the medical research company's stock worth $687,553,000 after acquiring an additional 114,277 shares during the last quarter. Finally, Cetera Trust Company N.A increased its holdings in Thermo Fisher Scientific by 3.3% in the 1st quarter. Cetera Trust Company N.A now owns 4,646 shares of the medical research company's stock worth $2,312,000 after acquiring an additional 150 shares during the last quarter. 89.23% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

TMO has been the subject of several analyst reports. UBS Group raised their target price on Thermo Fisher Scientific from $460.00 to $500.00 and gave the stock a "neutral" rating in a research note on Thursday, July 24th. Scotiabank upgraded Thermo Fisher Scientific from a "sector perform" rating to a "sector outperform" rating and set a $590.00 target price for the company in a research note on Friday, July 11th. HSBC restated a "hold" rating and issued a $510.00 target price on shares of Thermo Fisher Scientific in a research note on Thursday, July 24th. William Blair began coverage on Thermo Fisher Scientific in a research note on Monday, August 18th. They issued an "outperform" rating for the company. Finally, Hsbc Global Res cut Thermo Fisher Scientific from a "strong-buy" rating to a "hold" rating in a report on Thursday, July 24th. Sixteen investment analysts have rated the stock with a Buy rating and six have issued a Hold rating to the stock. According to MarketBeat.com, Thermo Fisher Scientific currently has an average rating of "Moderate Buy" and a consensus price target of $593.00.

Thermo Fisher Scientific Price Performance

Shares of Thermo Fisher Scientific stock traded down $5.90 during trading on Tuesday, hitting $486.82. 955,100 shares of the stock traded hands, compared to its average volume of 2,437,594. The company has a quick ratio of 1.50, a current ratio of 1.93 and a debt-to-equity ratio of 0.65. The stock has a market cap of $183.83 billion, a price-to-earnings ratio of 28.16, a PEG ratio of 2.63 and a beta of 0.75. The firm's fifty day moving average is $454.36 and its 200-day moving average is $453.50. Thermo Fisher Scientific Inc. has a 52 week low of $385.46 and a 52 week high of $627.88.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last announced its quarterly earnings data on Wednesday, July 23rd. The medical research company reported $5.36 EPS for the quarter, beating the consensus estimate of $5.22 by $0.14. The firm had revenue of $10.86 billion for the quarter, compared to analyst estimates of $10.68 billion. Thermo Fisher Scientific had a return on equity of 16.82% and a net margin of 15.24%.The company's revenue was up 2.9% on a year-over-year basis. During the same period in the prior year, the company earned $5.37 EPS. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. Research analysts expect that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Wednesday, October 15th. Investors of record on Monday, September 15th will be issued a dividend of $0.43 per share. The ex-dividend date is Monday, September 15th. This represents a $1.72 annualized dividend and a yield of 0.4%. Thermo Fisher Scientific's dividend payout ratio is currently 9.95%.

Insider Activity

In related news, CEO Marc N. Casper sold 10,000 shares of the stock in a transaction dated Friday, August 22nd. The stock was sold at an average price of $500.96, for a total transaction of $5,009,600.00. Following the completion of the sale, the chief executive officer directly owned 115,174 shares in the company, valued at $57,697,567.04. This represents a 7.99% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, EVP Gianluca Pettiti sold 400 shares of the stock in a transaction dated Friday, July 25th. The shares were sold at an average price of $479.98, for a total value of $191,992.00. Following the sale, the executive vice president owned 22,367 shares of the company's stock, valued at $10,735,712.66. This represents a 1.76% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 28,896 shares of company stock valued at $13,603,438 over the last 90 days. 0.33% of the stock is currently owned by company insiders.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.